Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, vernakalant (Brinavess®) cannot be endorsed for use within NHS Wales as treatment for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults: for non-surgery patients (atrial fibrillation ≤ 7 days duration); for post-cardiac surgery patients (atrial fibrillation ≤ 3 days duration). |
||
|
||
Medicine details |
||
| Medicine name | vernakalant (Brinavess®) | |
| Formulation | 20 mg/ml concentrate for solution for infusion | |
| Reference number | 572 | |
| Indication | For treatment for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults: for non-surgery patients (atrial fibrillation ≤ 7 days duration); for post-cardiac surgery patients (atrial fibrillation ≤ 3 days duration). |
|
| Company | Cardiome Pharma Corp | |
| BNF chapter | Cardiovascular system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 02/12/2010 | |